ScripActuate Therapeutics, Inc. grossed $22.4m from its initial public offering of 2.8 million shares priced at $8 each in the 15th biopharmaceutical company IPO in the US in 2024. It was not the smallest
ScripRivus Pharmaceuticals Inc. already had its lead Controlled Metabolic Accelerator (CMA), known as HU6, in a Phase IIa clinical trial last year when it raised $35m in series A venture capital. Now, wit
ScripITF Pharma , the US subsidiary of privately-held European specialty pharma Italfarmaco SPA , is gearing up to roll out Tiglutik – an easy-to-swallow liquid formulation of the mainstay amyotrophic l
ScripVenture capital investors put $2.2bn into 128 biopharmaceutical companies in the first quarter of this year and at the rate that VC firms are raising new funds, 2017 could be another big financing yea